Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio® for the Treatment of Gastric Cancer Poster presented at ASCO GI

Genome & Company North Korea United States of America South Korea California

Results showed partial response being confirmed in 7 out of 42 patientsPartial response was observed in 3 out of 8 patients who were previously treated by immunotherapy 

View original content:https://www.prnewswire.co.uk/news-releases/genome--company-announces-positive-topline-results-from-phase-2-clinical-trial-of-combination-of-gen-001-and-bavencio-for-the-treatment-of-gastric-cancer-poster-presented-at-asco-gi-302042227.html